About 40% of American will be diagnosed with cancer at some point in their lives. While this seems bleak, there are a number of amazing advances on the horizon that show great promise in battling this dreaded disease.
Tempus, co-founded by Eric Lefkofsky, is a company using data-enabled precision in its war on cancer. Lefkofsky had never experienced cancer up close and personal until his wife’s breast cancer diagnosis. He was astounded to learn the gap in data collection and digital technology. Although data is collected, there is no streamlined way to use it in an effective manner.
The goal of Tempus is to change the delivery of cancer care. The platform created by Tempus analyzes clinical and molecular data of the patient. Tempus has developed a line of software that utilizes optical character definition to doctor’s notes. This way the data is more structured and viable for care and treatment.
While the process has been around for quite some time, it is very expensive. In 2003, the process cost upwards of $1 million. The advancements made over the years have reduced the process to $5,000. The price is expect to drop even more in the next few years.
Many wonder why genome sequencing is so important. With cancer being fought on the molecular and cellular level, human genes can unlock the key to a cancer cure. As more and more data is researched and analyzed the closer researchers can get to a cure.
Lefkofsky and others working with precision medicine believe the technology will help doctors more accurately find treatments for patients. They will be able to better determine which medicines are more likely to work than others.
Eric Lefkofsky was born in Southfield, Michigan. He is a 1991 graduate of the University of Michigan. He is also a graduate of the University of Michigan Law School.